JenaValve Recaps Key Highlights Including Late-Breaking Clinical Data from New York Valves 2026

Early Temperature Rise Predicts Poor Stroke Outcomes

Can GLP-1 medications improve health in people with Type 2 diabetes and PAD?

Idorsia appoints Roland Wandeler as Chief Executive Officer

Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs

MarinHealth Launches the Haynes Heart and Vascular Institute, Marking a New Era in Cardiovascular Care for the North Bay

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

CV Imaging

Cardiovascular Risk Reduction

CVD Prevention